A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia

BMC Psychiatry

Rodrigo A Bressan²  André F Reis¹  Jair de Jesus Mari²  Mário Dinis Mateus²  Maria das Graças Miquelutti Camargo⁵  Andréa Freirias³  Sérgio Tamai³  Hélio Elkis⁵  Larissa C Martini²  Cecília Attux⁴ 

[1] Division of Endocrinology, Department of Medicine, Universidade Federal de São Paulo (UNIFESP). Rua Pedro de Toledo, 910, Vila Clementino, CEP 04039-002, São Paulo, (SP), Brazil;Department of Psychiatry, Universidade Federal de São Paulo. Rua Machado Bitencourt, 222, Vila Clementino, CEP 04044-000, São Paulo, (SP), Brazil;CAISM (Centro de Atenção Integrada à Saúde Mental) from Irmandade Santa Casa de Misericórdia de São Paulo, Rua Major Maragliano, 287, Vila Mariana, CEP 04017030, São Paulo, (SP), Brazil;Rua Borges Lagoa, 564 cj, 23 04038-000, São Paulo, SP, Brazil;Department and Institute of Psychiatry, University of São Paulo Medical School. Rua Dr. Ovídio Pires de Campos, 785 – Cerqueira César, CEP 05403010, São Paulo, (SP), Brazil

关键词: Physical activity;    Weight gain;    Clinical trial;    Schizophrenia;   

Others  :  1124133
DOI  :  10.1186/1471-244X-13-60

 received in 2012-10-08, accepted in 2013-02-13,  发布年份 2013

【 摘 要 】

Background

Patients with schizophrenia have lower longevity than the general population as a consequence of a combination of risk factors connected to the disease, lifestyle and the use of medications, which are related to weight gain.

Methods

A multicentric, randomized, controlled-trial was conducted to test the efficacy of a 12-week group Lifestyle Wellness Program (LWP). The program consists of a one-hour weekly session to discuss topics like dietary choices, lifestyle, physical activity and self-esteem with patients and their relatives. Patients were randomized into two groups: standard care (SC) and standard care plus intervention (LWP). Primary outcome was defined as the weight and body mass index (BMI).

Results

160 patients participated in the study (81 in the intervention group and 79 in the SC group). On an intent to treat analysis, after three months the patients in the intervention group presented a decrease of 0.48 kg (CI 95% -0.65 to 1.13) while the standard care group showed an increase of 0.48 kg (CI 95% 0.13 to 0.83; p=0.055). At six-month follow-up, there was a significant weight decrease of −1.15 kg, (CI 95% -2.11 to 0.19) in the intervention group compared to a weight increase in the standard care group (+0.5 kg, CI 95% -0.42–1.42, p=0.017).

Conclusion

In conclusion, this was a multicentric randomized clinical trial with a lifestyle intervention for individuals with schizophrenia, where the intervention group maintained weight and presented a tendency to decrease weight after 6 months. It is reasonable to suppose that lifestyle interventions may be important long-term strategies to avoid the tendency of these individuals to increase weight.

Clinicaltrials.gov identifier

NCT01368406

【 授权许可】

   
2013 Attux et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
• [2]Brown S, Birtwistle J, Roe L, Thompson C: The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999, 29:697-701.
• [3]Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003, 54:565-567.
• [4]Casey DE, Hansen TE: Excessive mortality and morbidity associated with schizophrenia. In Medical Illness and Schizophrenia. 2nd edition. Edited by Meyer JM, Nasrallah HA. Washington DC: American Psychiatric Publishing Inc; 2009:17-36.
• [5]Saha S, Chant D, McGrath J: A systematic review of mortality in schizophreniais the differential mortality gap worsening over time? Arch Gen Psychiatry 2007, 64:1123-1131.
• [6]Brown S, Kim M, Mitchell C, Inskip H: Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010, 196:116-121.
• [7]Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66:51-57.
• [8]Weiden PJ, Mackell JA, McDonnel DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 1872, 2003:1-7.
• [9]Bushe C, Haddad P, Peveler R, Pendlebury J: The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005, 19:28-35.
• [10]Faulkner G, Cohn T, Remington G: Interventions to reduce weight gain in schizophrenia. The Cochrane Library 2009, 04:Art. No. CD005148.
• [11]Tuomilehto J, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
• [12]Eriksson MK, Franks PW, Eliasson M: A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary caresetting. The Swedish Björknäs Study. PLoS ONE 2009, 4:e5195.
• [13]Damião R, Sartorelli DS, Hirai A, Bevilacqua MR, Salvo VL, Ferreira SR: Impact of a lifestyle intervention program on metabolic, anthropometrical and dietary profile of Japanese-Brazilians with and without metabolic syndrome. Arq Bras Endocrinol Metab 2011, 55:134-145.
• [14]American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2011, 34(1):S11-S61.
• [15]Attux C, Martini LC, Reis AF, Bressan RA: Intervenções não farmacológicas para manejo do ganho de peso em pacientes com esquizofrenia em uso de antipsicóticos. Arq Bras Endocrinol Metabol 2009, 53:391-398.
• [16]Álvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD: Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomized controlled trials. Br J Psychiatr 2008, 193:101-107.
• [17]Attux C, Martini LC, Araujo CM, Roma AM, Mullan EM: Non-pharmacological management of weight gain: a national, multicentric study for schizophrenia and severe mental disorders In: XIV Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, 2008, Montreux. Schizophr Res Amsterdam 2008, 98:52. Elsevier
• [18]Attux C, Martini LC, Araujo CM, Roma AM, Reis AF, Bressan RA: The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: results from a national multicentric study. Rev Bras Psiq 2011, 33:117-121.
• [19]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) New York: Biometrics Research, New YorkState Psychiatric Institute, November 2002. Schizophr Bull 1987, 13:261-276.
• [20]Kay SR, Flszbein A, Opfer LA: The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987, 13:261-276.
• [21]Ghiringhello MT, Vieira JGH, Tachibana TT, Ferrer C, Maciel RMB, Amioka PHC: Distribution of HOMA-IR in Brazilian Subjects with Different Body Mass Indexes. Arq. Bras. Endocrinol Metab. 2006, 50:573-574.
• [22]Bressan RA, Chaves AC, Shirakawa I, Mari JJ: Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. Schizophr Res 1998, 32:31-39.
• [23]Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB: The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003, 107:16-23.
• [24]Jones SH, Thornicroft G, Coffey M, Dunn G: A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995, 166:654-659.
• [25]Martini LC, Attux C, Bressan RA, Mari JJ: Cultural adaptation, reliability and validity of the Brazilian version Independent Living Skills Survey (ILSS-BR/P) in schizophrenia. Rev Psiquiatr Clin 2012, 39:12-18.
• [26]Fleck MPA, Fachel O, Louzada S, Xavier M, Chachamovich E, Vieira G: Desenvolvimento da versão em português do instrumento de avaliação de qualidade de vida da organização mundial da saúde (WHOQOL-100). Rev Bras Psiquiatr 1999, 21:19-28.
• [27]Dini GM, Quaresma MR, Ferreira LM: Adaptação Cultural e Validação da Versão Brasileira da Escala de Auto Estima de Rosemberg. Rev Soc Bras Cir Plast 2004, 19:41-52.
• [28]Roe L, Strong C, Whiteside C, Neil A, Mant D: Dietary intervention in primary care: validity of the DINE method for Diet Assessment. Fam Pract 1994, 11:375-381.
• [29]Carmo JT, Pueyo AA: A adaptação ao português do Fagerström test for nicotine dependence (FTND) para avaliar a dependência e tolerância à nicotina em fumantes brasileiros. Rev Bras Med 2002, 59:73-80.
• [30]Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35:1381-1395.
• [31]Kwon JS, Choi JS, Bahk WM, Kim CY, Kim CH, Shin YC: Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006, 67:547-553.
• [32]Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008, 299:185-193.
• [33]Porsdal V, Beal C, Kleivenes OK, Martinsen EW, Lindström E, Nilsson H, Svanborg P: The Scandinavian Solutions for Wellness study – a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry 2010, 10:42. BioMed Central Full Text
• [34]McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S: A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophr Res 2006, 86:36-44.
• [35]Wu MK, Wang CK, Bai YM, Huang CY, Lee SD: Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007, 58:544-550.
• [36]LeBlanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T: Effectiveness of primary care–relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:434-447.
• [37]Institute of Medicine: Weighing the options: criteria for evaluating weight management programs. Washington DC: National Academy Press; 1995.
• [38]Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG: The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003, 35:237-241.